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Background and purpose: The time dependency of the effect of 5-HT4 receptor agonists depends on many specific regulatory
mechanisms, which vary between tissues. This has important implications with regard to the effects of endogenous 5-HT, as
well as to the clinical use of 5-HT4 receptor agonists, and might contribute to tissue selectivity of agonists.
Experimental approach: The progression and desensitization of 5-HT4 receptor-mediated responses were evaluated in an
organ bath set-up using two, clinically relevant, porcine in vitro models: gastric cholinergic neurotransmission and atrial
contractility.
Key results: Exposure of gastric tissue to 5-HT or to the selective 5-HT4 receptor agonists prucalopride and M0003 results in
a sustained non-transient effect during exposure; after washout, the response to a subsequent challenge with 5-HT shows no
clear desensitization. Incubation of left atrial tissue with 5-HT resulted in a transient response, leading after washout to a marked
desensitization of the subsequent response to 5-HT. The selective 5-HT4 receptor agonists prucalopride and M0003 induce only
very weak atrial responses whereas they are very effective in desensitizing the atrial response to 5-HT. The observations also
suggest that the properties of prucalopride and M0003 to bind to and/or activate the 5-HT4 receptor differ from those of 5-HT.
This difference might have contributed to the observed desensitization.
Conclusions and implications: The high potency of prucalopride and M0003 in desensitizing the response to 5-HT together
with their low efficacy in the atrium emphasizes the cardiac safety of this class of 5-HT4 receptor agonists.
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Introduction
5-HT4 receptors arewidely expressed in the body and they exert
pleiotropic effects after being activated by their endogenous
ligand, 5-HT. Selective 5-HT4 receptor agonists therefore have a
large therapeutic potential to treat patients suffering from a
variety of diseases. Their beneficial effect mainly arises from
the interaction with neuronal 5-HT4 receptors, resulting in a
facilitation of neurotransmitter release in the brain and the
periphery. In the brain, 5-HT4 receptors reside mainly in the
limbic system. In animal models, their activation results in
increased acetylcholine release, suggesting a role for this recep-
tor inmemory and learning (Langlois and Fischmeister, 2003).
Also in the enteric nervous system of the gastrointestinal (GI)
tract, 5-HT4 receptor agonists are able to strengthen cholinergic
neurotransmission. Although the effects of 5-HT4 receptor
agonists go beyond the cholinergic system, their impact on the
enteric cholinergic axis is considered the predominant mecha-
nism by which 5-HT4 receptor activation stimulates peristaltic
reflex activity (Gershon and Tack, 2007). This mechanism has
been described in the human GI tract, for neurons innervating
the circular muscle layer of the human proximal stomach
(Leclere and Lefebvre, 2002a) and both muscle layers in the
colon (Prins et al., 2000; Leclere et al., 2005), and underlies the
clinical efficacy of 5-HT4 receptor agonists such as cisapride in
patients suffering from reflux or gastroparesis (Feldman and
Smith, 1987) and prucalopride in patients with chronic con-
stipation (Bouras et al., 1999; Schiller, 2004). The human heart
also accommodates a small population of muscular 5-HT4
receptors and 5-HT4 receptor agonists therefore have the
potential to affect cardiac contraction and relaxation param-
eters (Kaumann and Levy, 2006).
To be successful in clinical practice, 5-HT4 receptor agonists
should not show tachyphylaxis of their GI effects and should
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thus remain effective during the course of treatment and not
respond only to the initial doses. On the other hand, the
occurrence of such tachyphylaxis in tissues outside the
primary target, for example the heart, could reduce potential
side effects of the agonists. Tachyphylaxis, or desensitization,
denoting the attenuation of a biological response to sustained
or repeated intervention, results from various, often cell-type-
specific mechanisms that limit further stimulation of down-
stream effectors either by the inhibition of downstream
signalling or direct receptor inactivation. It is well established
that 5-HT4 receptors can desensitize (become inactivated)
upon stimulation by their ligands. As shown in recombinant
systems, the 5-HT4 receptor is initially uncoupled from G
proteins resulting in attenuation of the primary response (the
formation of cAMP). This process involves G protein-coupled
receptor kinase 2 (GRK2) without any requirement of the
kinase activity of GRK2 (Barthet et al., 2005); by binding to
the receptor and to the G protein, GRK2 presumably prevents
their interaction (Ferguson, 2007). In a second step, receptors
can be removed from the cell surface by endocytosis, a process
involving GRK2-dependent phosphorylation of the receptor
and the recruitment of b-arrestins (Barthet et al., 2005;
Ponimaskin et al., 2005). Interestingly, the use of heterolo-
gous cells clearly shows the cell-type dependence of 5-HT4
receptor desensitization, which is rapid and strong in CHO
cells (Mialet et al., 2003) and weak and slow in COS and
HEK293 cells, explained by low levels of GRK2 in these cells
(Barthet et al., 2005). GRK levels might also influence the
mechanism of receptor desensitization for certain agonists
within a given tissue, and thus influence functional selectivity
(Kelly et al., 2008). Additionally, the desensitization process is
dependent on the 5-HT4 receptor splice variant that is
involved (Mialet et al., 2003; Pindon et al., 2004).
These observations underscore the importance of studying
the desensitization process in native tissue. Unfortunately,
apart from two studies describing a rapid and homologous
desensitization of the adenylyl cyclase response in neurons
from the mouse colliculi (Ansanay et al., 1992) and the rat
oesophagus (Ronde et al., 1995), little information is avail-
able on the desensitization of 5-HT4 receptors in their natural
environment. It has been suggested, referring to two studies
by Kaumann et al. (1991) and Kaumann and Sanders (1994),
that 5-HT4 receptors in the human atrium desensitize to a
lesser extent. However, the studies from which the underly-
ing data were derived were not designed to address this ques-
tion. The limitations of recombinant expression systems are
also emphasized by the observation that, despite desensiti-
zation of 5-HT4 receptors in mouse coliculli neurons, a brief
application of 5-HT results in a prolonged cAMP-mediated
blockade of K+ channels (Ansanay et al., 1995), ending up in
a persistent enhancement of transmitter release. In the left
atrium, 5-HT4 receptor-induced responses have the opposite
fate. In this tissue, inotropic responses decrease over time
despite the continuous presence of the agonist. This phe-
nomenon presumably results from the recruitment of phos-
phodiesterases (PDEs) that rapidly quench any inotropic
response elicited by 5-HT4 receptor agonists (De Maeyer
et al., 2006a).
We have now evaluated the progression and desensitization
of 5-HT4 receptor-mediated responses in two clinically rel-
evant porcine in vitro models: gastric cholinergic neurotrans-
mission and left atrial contractility. The time dependency of
the effects of 5-HT and the selective 5-HT4 receptor agonists
prucalopride and M0003 (R149402) as well as their capacity to
reduce the responsiveness to 5-HT were compared in these
assays. Previously, the efficacy of both agonists was compared
in both assays with prucalopride showing full agonism in the
stomach and partial agonism in the atrium (De Maeyer et al.,
2006b). The degree of agonism is indeed tissue-dependent
and is related to differences in receptor density or coupling
efficiency (De Maeyer et al., 2008). Divergence of the desen-
sitization properties of these agonists from their activation
properties (De Maeyer et al., 2006b) might reveal functional
selectivity of desensitization (Kelly et al., 2008). Prucalopride
and M0003 (R149402; De Maeyer et al., 2006b) are two com-
pounds underdevelopment by Movetis NV currently in pre-
registration phase and phase 2 respectively. The pig was
chosen as an experimental model because, apart from
humans, it is one of the very few species available with cardiac
5-HT4 receptors.
Methods
Tissue preparation
All animal procedures and this study were approved by the
ethical committee from Johnson & Johnson Pharmaceutical
Research & Development, a division of Janssen Pharmaceu-
tica N.V., Beerse, Belgium and by the Ethical Committee for
Animal Experiments of the Faculty of Medicine and Health
Sciences, Ghent University.
Female pigs (10–11 weeks, 22–27 kg), obtained from local
farms, were anaesthetized with an intravenous (50 mg kg-1)
sodium pentobarbital (Kela N.V., Hoogstraten, Belgium) injec-
tion. After exsanguination, the heart and the entire stomach
were dissected and placed in Krebs-Henseleit solution (com-
position in mmol·L-1: glucose 11.1, CaCl2 2.51, NaHCO3 25,
MgSO4 1.18, KH2PO4 1.18, KCl 4.69, EDTA 0.033 and NaCl
118). The preparation of muscle strips from the left atrium
and the proximal stomach was essentially as described before
(De Maeyer et al., 2006a,b). All tissues were used on the day of
preparation.
Left atrium Briefly, under continuous aeration, left atrial pec-
tinate muscles (9–12 per left atrium) with a thickness <1 mm
and a length varying between 3 and 7 mm were dissected
away from the endocardial surface. Tissues were suspended
in 20 mL organ baths containing Krebs-Henseleit solution at
37°C and oxygenated with 95% O2 and 5% CO2. The prepa-
rations were continuously electrically stimulated using two
platinum wire electrodes [0.5 Hz, 5 ms, just above threshold
voltage, resting length being half of Lmax, the length at
which maximal active tension was developed upon electrical
field stimulation (EFS)], except during wash steps. Before
starting the experimental protocol, the bath solution was
routinely supplemented with propranolol (0.2 mmol·L-1), to
avoid b-adrenoreceptor-mediated effects due to released
noradrenaline and cocaine (6 mmol·L-1), to inhibit the
uptake of 5-HT.
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Proximal stomach Gastric muscle strips of approximately
1.5 cm in length were prepared from the ventral side of the
proximal stomach in the direction of the longitudinal muscle
layer and stripped of the mucosa and most of the circular
muscle layer. The longitudinal muscle strips were mounted
between two coaxially aligned platinum wire electrodes under
a resting tension of 20 mN in organ baths containing 20 mL
of continuously aerated, Krebs-Henseleit solution which was
kept at 37°C. The bath solution also contained the nitric
oxide (NO) synthase inhibitor NG-nitro-L-arginine-
methylester (L-NAME; 0.1 mmol·L-1), to avoid functional
antagonism by the release of endogenous NO and 1 mmol·L-1
indomethacin to avoid prostaglandin-mediated contractions.
Viability of the tissue was checked with carbachol
(3 mmol·L-1), administered at 30 min intervals until two
similar successive responses to carbachol were obtained
(usually three times). After the last washing step organ baths
were supplied with 1 mmol·L-1 of methysergide, a 5-HT1,
5-HT2, 5-ht5, 5-HT6 and 5-HT7 receptor [nomenclature accord-
ing to Alexander et al. (2008)] antagonist, 0.3 mmol·L-1 of the
5-HT3 receptor antagonist granisetron and 6 mmol·L-1 cocaine,
to reduce the uptake of 5-HT by nerve endings. Thirty
minutes later, the gastric muscle strips were electrically stimu-
lated (every 3 min a 10 s pulse train at 4 Hz, 0.5 ms and 20 V).
Once successive electrically evoked contractions became
reproducible, the applied voltage was adjusted to reduce the
contraction force to 50% of the force developed at 20 V and
the electrical stimulation was set on hold for 20 min. EFS was
then reinstated at this adjusted voltage and from then on, this
electrical stimulation pattern was maintained.
Changes in isometric force of the preparations were
recorded via Statham UC2 force transducers (Gould, Cleve-
land, USA) and DBA 18 digital bridge amplifiers (Anerma,
Belgium) on a Powerlab data acquisition system and
recorded using Chart v5.1.1 software. EFS was performed
with a constant voltage stimulator (Janssen Pharmaceutica,
Belgium).
Experimental desensitization protocols
The applied protocols followed the previously described
methods to study 5-HT4 receptor desensitization in native
cells or tissue (Ansanay et al., 1992; Ronde et al., 1995) and are
illustrated in the Figures. Responses were monitored during
the complete duration of the experiment. In all protocols,
parallel preparations were exposed to increasing concentra-
tions of 5-HT4 receptor agonists (desensitization period). The
choice of the range of desensitizing concentrations for the
atrium was determined in preliminary experiments. For
experiments with gastric tissue, this was not possible (as there
was no desensitization) and the range of desensitizing con-
centrations was chosen 1 log unit lower than in the atrium
because the agonists are more potent in gastric tissue (De
Maeyer et al., 2006b). After removal of the agonists, tissues
were challenged with a fixed concentration of 5-HT (test
period). A submaximal concentration (as determined from
previously obtained non-cumulative concentration-response
curves) was chosen as the test concentration, being 1 mmol·L-1
in the atrium and 3 nmol·L-1 in the stomach (De Maeyer et al.,
2006a,b).
Proximal stomach
Protocol A The protocol was initiated by changing the physi-
ological bathing solution. Seven EFS trains (20 min) were
then obtained, followed by challenging parallel tissues with
different concentrations of 5-HT, prucalopride or M0003.
After 1 h (desensitization period), incubation was terminated
by three 1 min washes with fresh physiological solution and
after recovery of stable response to EFS (seven EFS trains), a
test concentration of 3 nmol·L-1 5-HT was administered and
left in contact with the tissues for at least 20 min (test
period).
Protocol B The protocol was initiated by changing the physi-
ological bath solution, followed by seven EFS trains before the
addition of a control concentration of 3 nmol·L-1 5-HT
(control period). When the maximal potentiating effect of
5-HT on the EFS-induced contractions was reached (seven EFS
trains), the tissues were washed with physiological solution
and allowed to recover for 1 h, during which time they were
washed every 15 min. Next, different desensitizing concentra-
tions of 5-HT were added to parallel tissues (desensitization
period). After 1 h, incubation was terminated by three 1 min
washes with fresh physiological solution and after recovery of
stable response to EFS (seven EFS trains), a test concentration
of 3 nmol·L-1 5-HT was administered and left in contact with
the tissues for at least 20 min (test period). A representative
tracing of an experiment performed according to protocol B is
shown in Figure 1a.
The susceptibility of the responses in the stomach to rever-
sal by the administration of a selective 5-HT4 receptor antago-
nist was examined by adding GR113808 (0.1 mmol·L-1) 1 h
after the administration of the agonists.
Left atrium
Protocols A and B Protocols A and B in this tissue were similar
to protocols A and B in the proximal stomach, except that
1 mmol·L-1 5-HT was used as control and test concentration
and that the protocol was ended by the administration of a
saturating concentration of isoprenaline (0.1 mmol·L-1). The
maximal response to the control concentration of 5-HT was
reached in 2–3 min. During wash steps, EFS was set on hold.
Time for recovery of a stable EFS-induced response after rein-
stating EFS was between 10 and 15 min. The test concentra-
tion was left in contact with the tissues for approximately
6 min. A representative tracing of an experiment performed
according to protocol B is shown in Figure 1b.
Protocol C Nine consecutive concentrations of 5-HT, includ-
ing a solvent concentration, were added as a single concen-
tration to parallel left atrial pectinate muscles and the
response was followed for 30 min (desensitization period).
Tissues were washed three times by changing the bath solu-
tion every minute under non-EFS conditions. EFS was rein-
stated and once a stable response was obtained (10–15 min), a
cumulative concentration-response curve to 5-HT with half
log units ascending concentration increments was established
(test period). Experiments were terminated by the administra-
tion of a saturating concentration of isoprenaline
(0.1 mmol·L-1). The same protocol was also performed in the
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Figure 1 Representative tracings showing experiments with 5-HT according to protocol B with longitudinal muscle strips of the proximal
stomach (a) or left atrial pectinate muscles (b). A control (C) concentration of 3 nmol·L-1 (a) or 1 mmol·L-1 (b) 5-HT (control period) was
administered and when the maximal potentiating effect of 5-HT on the EFS-induced contractions was reached, the tissues were washed (W)
with physiological solution and allowed to recover for 1 h, during which time they were washed every 15 min. Next, solvent or a desensitizing
concentration of 0.3 mmol·L-1 or 1 mmol·L-1 (a) or 1 mmol·L-1 or 3 mmol·L-1 (b) 5-HT was added. After 1 h, incubation was terminated by three
1 min washes with fresh physiological solution and after recovery of a stable response to EFS, a test concentration of 3 nmol·L-1 (a) or
1 mmol·L-1 (b) 5-HT was administered. The atrial experiments were terminated by the administration of 0.1 mmol·L-1 isoprenaline (ISO). The
increase in the level of the EFS-induced contractions at time point y (before administration of T) versus time point x (before administration of
C) in gastric tissue (a) is indicated by dashed lines.
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presence of the non-selective PDE inhibitor 3-isobutyl-1-
methylxanthine (IBMX, 20 mmol·L-1).
Data analysis
Electrically induced gastric contractions were expressed as
means of the contraction amplitude. Atrial contractions were
analysed using the peak of positive force derivative, i.e. the
contraction velocity (+dF·dt-1), rather that the contraction
force because the latter is also dependent on the relaxation
phase and a hastening of relaxationmight appear as a negative
inotropic effect. The average contraction to two EFS trains
(stomach) or contraction velocity during 2 min (left atrium)
before the addition of agonist was taken as the basal value.
Responses to 5-HT, prucalopride and M0003 (i.e. increase in
amplitude of the electrically induced gastric contractions, and
increase in +dF·dt-1 for the electrically induced atrial contrac-
tions) were expressed relative to the basal value per se for gastric
experiments or relative to the increase above the basal value
caused by 0.1 mmol·L-1 isoprenaline for atrial experiments.
To follow the time course of the drug-induced changes in
lusitropy, variations in contraction and relaxation must be
considered simultaneously because changes in the contrac-
tion phase induce coordinated changes in the relaxation
phase and the peak of the negative force derivative, -dF·dt-1,
cannot assess the isometric relaxation independently of the
contraction phase. We therefore analysed the coefficient
R2 = (+dF·dt-1)/(-dF·dt-1) which tests the coupling between
contraction and relaxation under high load and thus the
lusitropic state under high load in a manner that is less depen-
dent on inotropic changes (Hanouz et al., 2004). When the
muscle contracts isometrically, sarcomeres shorten very little.
Because of an increased sensitivity of myofilament for Ca2+
in such heavy loading conditions, the relaxation time course
is mainly determined by Ca2+ dissociation from troponin C
rather than by Ca2+ sequestration by the sarcoplasmic reticu-
lum (SR) or Ca2+ extrusion via Na+/Ca2+ exchange. Thus, R2
indirectly reflects myofilament calcium sensitivity (Mattiazzi
et al., 1986; Hanouz et al., 2004).
Statistical methods
Concentration-response curves were fitted to the Hill equa-
tion using GraphPad Prism v4.02. The same software was used
for statistical analysis. Unless otherwise stated, data are pre-
sented as mean  SEM, based on results from six different
animals. Comparisons between different pre-treatment
groups were made using one-way ANOVA with a post hoc Dun-
nett’s multiple comparison test to compare different groups
against the solvent-treated tissues. Concentration depen-
dency was tested with a post hoc test for a trend between mean
and column number. Significance is associated with a
P-value < 0.05. Of note, GraphPad Prism v4.02 never reports a
P-value < 0.001 for the Dunnett’s test for which P < 0.01 is the
limit. Concentration dependency of desensitization was sta-
tistically verified post hoc by a test for a trend between mean
and column number.
Drugs
The following drugs were used (abbreviations and respec-
tive suppliers in parentheses): 3-isobutyl-1-methylxanthine
(IBMX) and L-NG-nitro-arginine methyl ester (L-NAME; Fluka,
Switzerland); propranolol HCl (Sigma, Belgium); methyser-
gide maleate (Research Biochemical INS, USA); indomethacin
(Merck Belgolabo N.V.); [1-[2-[(methylsulphonyl)amino]
ethyl]-4-piperidinyl]methyl 1-methyl-1H-indole-3-carboxy-
late (GR 113808 ; Tocris Cookson, UK); 5-hydroxytryptamine
creatinine sulphate (5-HT; Acros Chimica, Belgium); cocaine
HCl, granisetron HCl, isoprenaline HCl, prucalopride HCl,
4-amino-5-chloro-2,2-dimethyl -2,3-dihydro-benzofuran-7-
carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-
4ylmethyl]-amide (M0003, previously R149402) and
carbachol (Johnson & Johnson Research and Development,
Beerse, Belgium). All compounds were dissolved and diluted
in distilled water, except for GR113808 and indomethacin.
GR113808 was freshly dissolved in dimethyl sulphoxide to
obtain a stock solution of 10 mmol·L-1; dilutions were made
with distilled water; indomethacin was dissolved in 9.1 mL
distilled water supplemented with 0.9 mL 2% Na2CO3. These
solutions were stored at -20°C.
Results
The capacity of 5-HT and the selective 5-HT4 receptor agonists
prucalopride and M0003 to reduce the responsiveness to 5-HT
was studied in gastric muscle strips and left atrial pectinate
muscles. Unless otherwise stated, experiments were performed
according to protocol A, as described in the methods section.
Agonist-induced desensitization of the response to 5-HT in
gastric tissue
5-HT Activation of 5-HT4 receptors with 5-HT (30 nmol·L-1 to
1 mmol·L-1) in porcine gastric muscle strips resulted in an
enhancement of EFS-induced muscle contractions. The
maximal increase was rapidly reached (6 min or two EFS
trains) and was preserved during the 1 h exposure time. Con-
sistent with our previous results, despite the presence of
methysergide and granisetron, 5-HT also induced a tonic con-
traction that was previously shown to be insensitive to
GR113808 (De Maeyer et al., 2006b). This is in line with a
study of Janssen et al. (2002) who showed the involvement of
an uncharacterized receptor and of the 5-HT2A receptor in the
basal contractile response to 5-HT.
Washout of 5-HT returned the EFS-induced response to a
level not different from that in control strips, although a
tendency to a remaining increase in basal response can be
observed in the strips that received 0.3 and 1 mmol·L-1 5-HT
(Figure 2a). Re-exposing the tissues to 3 nmol·L-1 5-HT showed
an apparent concentration-dependent (P < 0.001) loss of effi-
cacy, coinciding with the trend in increased baseline levels.
When responses were expressed relative to the initial baseline,
that is, before the addition of desensitizing agent, no signifi-
cant effect on efficacy could be demonstrated (Figure 2c).
However, a trend towards a desensitizing response was visible.
To clarify this ambiguity, the desensitizing potential of
5-HT was analysed using protocol B (Figures 1a and 3a), in
which each muscle strip first receives a control concentration
of 5-HT (3 nmol·L-1) followed by 1 h recovery period with
extensive washing, after which the protocol continues as
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described above. In a control strip it was confirmed that after
the 1 h recovery period, the response to 3 nmol·L-1 5-HT was
not yet affected. Within each tissue, responses to the 5-HT test
application were compared with the effect of the control
application (Figures 1a and 3a). This experiment confirmed
that responses only apparently desensitized (P < 0.001)
because of the maintained increase in basal response before
adding the test concentration. This is also clearly demon-
strated by the apparently reduced response to 5-HT in the
solvent-treated strips (Figure 3a), resulting from the increase
in EFS-induced contractions (drift) during the desensitization
period with solvent (Figures 1a and 2a).
In order to maximize comparability with the atrial experi-
ments, we also performed the above-described experiments
with 10 mmol·L-1 5-HT as the desensitizing concentration. The
experiments with protocol A showed that 10 mmol·L-1 5-HT
increased the EFS-induced contractions above the maximum
of the previously obtained concentration-response curve
(87.1  8.1%; DeMaeyer et al., 2006b). Also in strips that only
weakly responded to EFS (<2 g), 5-HT induced a robust increase
in the EFS-induced response, resulting in a large variation
when the responseswere expressed as% increase, ranging from
76% to 1019% with a median value of 242% (n = 11 tissues
from three animals); this response did not fade during the 1 h
exposure. The 5-HT4 receptor antagonist GR113808 (even in a
concentration of 3 mmol·L-1) was unable to affect this increased
response when administered 1 h after the administration of
5-HT. This is in contrast with the results obtained for all 5-HT
D
 max response response after 1h response after WO (y)
S -7.5 -7 -6.5 -6
0
20
40
60
80
100
Log [5-HT]
desensitizing concentration
F
o
r c
e
in
cr
e
a
se
(%
)
Atrium
S -7.5 -7 -6.5 -6
0
10
20
30
40
50
60
** **
Log [5-HT]
desensitizing concentration
re
sp
o
n
se
to
5
-H
T
(3
n
m
o
l·L
–1
)
F
or
ce
 in
cr
ea
se
 (
%
)
b
c d
yx
(ISO)
5-HT 5-HT
1 hour
W T(a, b) (c, d)
S -6.5 -6 -5.5 -5
-10
0
10
20
30
40
50
60
70
**
**
**
**
**
**
Log [5-HT]
desensitizing concentration
re
sp
o
n
se
t o
5
-H
T
( 1
mm
o
l·L
–1
)
+
dF
/d
t i
nc
re
as
e 
(%
)
Stomach Atrium
Stomacha
Eff (x)
App (y)
S -6.5 -6 -5.5 -5
-20
0
20
40
60
80
Log [5-HT]
desensitizing concentration
+
d
F
/ d
t
in
cr
e
a
se
(%
)
Figure 2 Desensitization of the 5-HT4 receptor-mediated responses induced by 5-HT in longitudinal muscle strips of the proximal stomach
(a, c) and left atrial pectinate muscles (b, d). The protocol (protocol A) of the desensitization experiment is illustrated at the top of the figure.
Gastric and atrial tissues were incubated with solvent (S) or different concentrations of 5-HT for 1 h (desensitization period from D to W). The
maximal effect of this treatment as well the response after 1 h, at the end of the desensitization period, is shown for stomach (a) and atrium
(b). All responses are expressed relative to the basal tissue response at time point x. After 1 h, tissues were washed (W) to remove 5-HT; the
remaining tissue response at time point y is shown in (a) and (b). The effect of pre-treatment with 5-HT on the response to a subsequent
exposure to 5-HT (test period T: 3 nmol·L-1 in stomach and 1 mmol·L-1 in left atrium) is shown in (c) and (d). Responses were expressed relative
to the baseline at time point y, named apparent desensitization (App) as well as to the baseline at time point x, named effective desensitization
(Eff). In (c), the level of the baseline at time point y, which is also shown in (a), is marked by a line in the bar showing the response relative
to the baseline at time point x. Atrial experiments were terminated by the administration of a supramaximal concentration of isoprenaline
(0.1 mmol·L-1) and responses were expressed relative to the effect caused by this b-adrenoreceptor agonist. **P < 0.01 versus solvent treated
tissues (Dunnett).
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concentrations up to 1 mmol·L-1 5-HT which were all at least
partially reversed by 0.1 mmol·L-1 GR113808 (previous experi-
ments, results not shown). This result greatly hampers inter-
pretation of the results as well as comparison with the other
desensitizing concentrations of 5-HT, because other than
5-HT4 receptors appear to be involved.
Prucalopride and M0003
Prucalopride and M0003 concentration-dependently
increased the EFS-induced cholinergic contraction, an effect
that was sustained for 1 h and, in contrast to 5-HT, after
removal of the agonists by three washes (Figures 4a and 5a).
Consequently, 15 min after ending the desensitizing expo-
sure, control tissues displayed smaller contractions than
tissues pre-treated with prucalopride or M0003. Application
of GR113808 (0.1 mmol·L-1) before washing reversed the
effects induced by the agonists (illustrated in Figure 6 for
prucalopride). In strips pre-treated with the agonists, applica-
tion of 3 nmol·L-1 5-HT, 15 min after the wash step, induced
only a limited additional increase of the contraction force,
decreasing with higher pre-treatment concentrations of the
agonist (P < 0.001; Figures 4c and 5c). However, when these
responses were expressed relative to baseline contractions
before the desensitization period, responses were constant
(Figures 4c and 5c), or even increased (after 3 nmol·L-1 of
M0003; Figure 5c). These observations thus indicate that the
potentiating effects of prucalopride and M0003 on electrically
induced contractions are wash-resistant and that the apparent
reduced response to 5-HT is a reflection of this wash resis-
tance. This is only reflected by the apparently reduced
response to 5-HT in solvent-treated tissues.
Agonist-induced desensitization of the response to 5-HT
in atrial tissue
5-HT As previously described (De Maeyer et al., 2006a), 5-HT
induced a transient increase in the electrically induced con-
tractile response in atria. After reaching a maximum within
2 min, the atrial contractile response rapidly returned to basal
(Figure 2b). When the strips were subsequently exposed to
1 mmol·L-1 5-HT, a loss of efficacy was observed dependent on
the preceding desensitizing 5-HT concentration (P < 0.001)
and irrespective of the chosen baseline value (Figure 2d). The
pDC50 (negative logarithm of the concentration at which
the response was reduced by 50%) was 6.2  0.2. As with the
gastric preparations, these results were confirmed in atria by
experiments performed according to protocol B (Figures 1b
and 3b). Thus, after the 1 h recovery period upon washout of
the 5-HT control (C) concentration, the response to
1 mmol·L-1 5-HT was not yet affected (middle tracing of
Figure 1b). The pDC50 in this protocol was 6.3  0.2.
To elucidate whether the diminishing response to a fixed
concentration of 5-HT upon pre-incubation of left atrial tra-
beculae with 5-HT was due to an effect on potency, efficacy or
both, a full concentration-response curve to 5-HT was elicited
during the test period (protocol C). Pre-treatment with 1, 3
and 10 mmol·L-1 5-HT caused a reduction of the maximum as
well as a rightward shift of the bell-shaped concentration-
response curve (Figure 7c,e; Table 1). Similar results were
obtained when the experiments were conducted in the pres-
ence of 20 mmol·L-1 IBMX to assess the desensitizing potential
of 5-HT in the absence of any involvement of PDEs: a right-
ward shift of the (non-bell-shaped) concentration-response
curve as well as a reduction of the maximal response after
pre-treatment with 1–10 mmol·L-1 5-HT (Figure 7d,f; Table 1).
Interestingly, in the presence of IBMX, 5-HT responses
showed a concentration-dependent wash-resistance (compare
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Figure 3 Desensitization of the 5-HT4 receptor-mediated responses
induced by 5-HT in longitudinal muscle strips of the proximal
stomach (a) and left atrial pectinate muscles (b). The protocol (pro-
tocol B) of the desensitization experiment is illustrated at the top of
the figure. Gastric and atrial tissues were challenged with 3 nmol·L-1
or 1 mmol·L-1 5-HT (control period C to W) respectively followed by
1 h recovery period with extensive washing. Next, tissues were pre-
incubated with solvent (S) or different concentrations of 5-HT for 1 h
(desensitization period D to W). After washing, the effect to
3 nmol·L-1 or 1 mmol·L-1 5-HT (test period T) respectively was
assessed. The response was expressed as a percentage of the 5-HT-
induced contractions in the same tissue in the absence of any desen-
sitization, that is, during the control period (taken as 100%).
Responses were expressed relative to the baseline at time point y,
named apparent desensitization (App) as well as to the baseline at
time point x, named effective desensitization (Eff). In (a), the level of
the baseline at time point y is marked in the effective desensitization
bar (also expressed as a percentage of the maximal 5-HT-induced
contraction during the control period). Atrial experiments were ter-
minated by the administration of a supramaximal concentration of
isoprenaline (0.1 mmol·L-1) and responses were expressed relative to
its effect. The maximal contraction induced by 5-HT in the control
period (C to W) was 39  2% (contraction force increase) and
56  3% (maximal contraction velocity increase relative to the
increase caused by isoprenaline) in gastric and atrial tissue respec-
tively. *P < 0.05, **P < 0.01 versus solvent treated tissues (Dunnett).
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the 30 min response in Figure 7b with baseline responses in
Figure 7d; P < 0.05 for 0.1 mmol·L-1 5-HT and P < 0.01 for
1 mmol·L-1 5-HT). Therefore, the effect on the maximal
response largely depends on the representation of the data
(Figure 7d,f). GR113808 was able to reverse the maintained
response to 5-HT (results not shown). In the experiments with
IBMX, IBMX by itself increased the inotropic response from
295  18 mN·s-1 to 421  27 mN·s-1 (n = 53, P < 0.0001), and
responses were measured relative to this increased baseline.
Prucalopride and M0003
Prucalopride exerted positive inotropic effects on the atrial
preparations, which were considerably weaker than those
induced by 5-HT (Figure 4b). No significant effect on the atrial
contraction force was observed with M0003 (Figure 5b).
However, despite the weak inotropic response, both com-
pounds had a conditioning influence on the tissue as after
their removal by repeatedly changing the bath solution, the
response to 1 mmol·L-1 5-HT was diminished, the degree of
decrease correlating with the pre-treatment concentration
(P < 0.001; Figure 4d and 5d). The pDC50 for the cross-
desensitization of the 5-HT response was 7.5  0.1 and
8.4  0.1 for prucalopride and M0003 respectively.
Lusitropy and variation of R2 ratios
In contrast to the transient positive inotropic response, acti-
vation of atrial 5-HT4 receptors by the desensitizing sub-
stances (5-HT, prucalopride and M0003) resulted in a
sustained lusitropic response (results not shown), that is, a
larger effect on the relaxation phase than on the contraction
phase of the contraction-relaxation cycle and hence a
decrease in R2. After washout, the lusitropic state of the
tissues remained elevated, as illustrated by the sustained sig-
nificant decrease of the contraction-relaxation coupling
parameter R2 (Figure 8).
In experiments with IBMX, IBMX itself caused a reduction
of R2 from 1.39  0.02 to 1.28  0.02 (n = 51, P < 0.0001). As
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Figure 4 Desensitization of the 5-HT4 receptor-mediated responses induced by prucalopride in longitudinal muscle strips of the proximal
stomach (a, c) and left atrial pectinate muscles (b, d). The chemical structure of prucalopride and the protocol of the desensitization experiment
are illustrated at the top of the figure. Further explanation is as for Figure 2 except that prucalopride was used instead of 5-HT during the
desensitization period. *P < 0.05, **P < 0.01 versus solvent treated tissues (Dunnett).
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also previously reported (De Maeyer et al., 2006a), under this
condition no further decrease of R2 occurred after the addi-
tion of 5-HT, or prucalopride. Actually, R2 rather increased
upon addition of a high concentration of 5-HT or prucalo-
pride in the presence of IBMX. This was also observed after
the addition of isoprenaline at the end of the protocol (results
not shown).
Discussion and conclusions
The progression and desensitization of 5-HT4 receptor-
mediated responses were evaluated in two clinically relevant
in vitro models: a porcine GI model of cholinergic neurotrans-
mission (De Maeyer et al., 2006b), and the porcine atrium.
Summarized, our results show that exposure of the gastric
tissue to 5-HT or selective 5-HT4 receptor agonists results in a
sustained, non-transient effect during exposure; after washout
this does not result in a clear desensitization of the response
to a subsequent challenge with 5-HT. Incubation of left atrial
tissue with 5-HT results in a transient response, after washout
leading to a potent desensitization of the subsequent response
to 5-HT. The selective 5-HT4 receptor agonists prucalopride
and M0003 induced only very weak atrial responses but
appeared very effective in desensitizing the response to 5-HT.
Our observations also suggest that the properties of prucalo-
pride and M0003 to bind and activate the 5-HT4 receptor
differ from those of 5-HT, and this might have contributed to
the observed desensitization.
Stomach
In the gastricmuscle preparations, 5-HT4 receptors are presum-
ably located presynaptically on myenteric cholinergic nerves
(De Maeyer et al., 2006b). By facilitating the release of acetyl-
choline, their activation results in a reinforcement of muscle
contraction through activation of M3 receptors on
the smooth muscle cells (Leclere and Lefebvre, 2002b). 5-HT,
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S -9 -8.5 -8 -7.5 -5
0
20
40
60
80
****
****
**
**
** **
** **
Log [M0003]
desensitizing concentration
re
s p
o
n
s e
to
5
-H
T
(1
m
o
l·L
–1
)
+
dF
/d
t i
nc
re
as
e 
(%
)
S -9 -8.5 -8 -7.5 -5-20
0
20
40
60
80
Log [M0003]
desensitizing concentration
+
d
F
/d
t
in
cr
e
a
s e
(%
)
S -10 -9.5 -9 -8.5
0
10
20
30
40
50
60
70
Log [M0003]
desensitizing concentration
F
o
rc
e
in
cr
e
a
se
(%
)
yx
(ISO)
M0003 5-HT
1 hour
D W T(a, b) (c, d)
Atriumb
c d muirtAhcamotS
Stomacha
Eff (x)
App (y)
Cl
NH2O
CH3
CH3
NH
O
N
OH
O
CH3
S -10 -9.5 -9 -8.5
0
10
20
30
40
50
60
70
*
**
** **
*
Log [M0003]
desensitizing concentration
re
sp
o
n
se
to
5
- H
T
(3
n
F
or
ce
 in
cr
ea
se
 (
%
)
re
sp
o
n
se
t o
5
-H
T
(1
m
+
dF
/d
t i
nc
re
as
e 
(%
)
+
d
F
/d
t
in
cr
e
a
se
(%
)
F
o
rc
e
in
cr
e
a
se
(%
)
re
sp
o
n
se
to
5
- H
T
(3
n
m
o
l·L
–1
)
F
or
ce
 in
cr
ea
se
 (
%
)
Figure 5 Desensitization of the 5-HT4 receptor-mediated responses induced by M0003 in longitudinal muscle strips of the proximal stomach
(a, c) and left atrial pectinate muscles (b, d). The chemical structure of M0003 and the protocol (protocol A) of the desensitization experiment
are illustrated at the top of the figure. Further explanation is as for Figure 2 except that M0003 was used in stead of 5-HT during the
desensitization period. *P < 0.05, **P < 0.01 versus solvent treated tissues (Dunnett).
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prucalopride and M0003 all persistently increased the cholin-
ergic contraction of the gastric muscle strips, confirming our
previous observations (De Maeyer et al., 2006b). This suggests
either the absence of receptor desensitization or the sustained
activation of a mechanism downstream of the receptor. In the
latter scenario, the 5-HT4 receptors themselves could well be
desensitized while the response initiated by their activation
is not. Indeed, in spite of a rapidly desensitizing adenylyl
cyclase response to 5-HT4 receptor activation in mouse colli-
culi neurons (Ansanay et al., 1992), their activation does result
in long-term effects. In these cells, a 1 min application and
washout of 5-HT causes a 5-HT4 receptor-mediated transient
protein kinase A (PKA) response and a long-lasting
inhibition of phosphatases resulting in a progressive and long-
lasting blockade of K+ channels (Ansanay et al., 1995). Simi-
larly, the effect of prucalopride appeared to be wash-resistant
in rat hippocampal slices (Spencer et al., 2004). In our experi-
ments, the effects mediated by prucalopride and M0003 were
also resistant to drug washout, theoretically corresponding
with the possibility of sustained facilitation of transmitter
release by these two drugs via amechanism downstream of the
receptor. However, two observations cast doubt on the validity
of this hypothesis in the gastric preparations. First, the phe-
nomenon is absent for 5-HT as the effects induced by 5-HT
were reversed after washout of the drug (regardless of a small
trend for 0.3 and 1 mmol·L-1 5-HT). Second, the 5-HT4 receptor
antagonist GR113808 was able to nullify the sensitized cho-
linergic contractions before and after (results not shown)
washout of the drugs, suggesting that the receptors are still
active. In colliculi neurons, the effect of 5-HT was abolished by
pre-incubation with a 5-HT4 receptor antagonist, but its effect
was not reversed when the antagonist was applied during
washout of the drug (Ansanay et al., 1995). In our experi-
ments, an activated state of the receptor is thus required to
sustain the response and no long-term effect on a downstream
effector has occurred. There may be a mechanistic analogy
with the colon because Cellek et al. (2006) have described the
non-transient effect of prucalopride on cholinergic contrac-
tions and nitrergic relaxations in the human colon, both
effects being reversed upon administration of a 5-HT4 receptor
antagonist. The observation that application of 5-HT, 15 min
after a conditioning application of 5-HT, prucalopride or
M0003 had an additional facilitatory effect on the EFS-
induced contractions resulting in similar EFS-induced contrac-
tions as in solvent-treated strips also argues against the
occurrence of desensitization; in other words, the maximal
response was always reached, whatever the level of the basal
value. It is also possible that because of the high receptor
reserve for 5-HT in this preparation (De Maeyer et al., 2006b),
5-HT4 receptor desensitization has only moderate effects on
the agonist-induced responses. Similarly, we cannot exclude
the possibility that receptors already have been (partially)
resensitized, because in colliculi neurons and CHO cells,
partial recovery of the 5-HT4 receptor-induced cAMP produc-
tion was already observed after 30 min (Ansanay et al., 1992;
Mialet et al., 2003); because of the high receptor reserve for
5-HT in the stomach, only part of the receptors need to be
operational again to achieve the same tissue response.
The experiments with 10 mmol·L-1 5-HT show that at this
concentration, a receptor that is resistant to high concentra-
tions of GR113808 is involved in the EFS-induced responses.
Because our experiments were performed in the presence of
granisetron and methysergide, 10 mmol·L-1 5-HT either sur-
mounts antagonism by these antagonists, or an unknown
5-HT receptor is involved. The tonic contractile response to
5-HT in the same preparation as used in this study has previ-
ously been shown to be mediated by 5-HT2A and a receptor
that could not be characterized (Janssen et al., 2002).
It appears that prucalopride and M0003 are unique 5-HT4
receptor agonists in that they interact with the receptor both
in an antagonist-reversible but wash-resistant manner.
Although we cannot exclude the possibility that the com-
pounds partition into biological membranes, resulting in the
development of a substantial depot of agonist that exhibits
relative resistance to washing, we question this explanation
because the hydrophobicity of prucalopride, M0003 and 5-HT
is comparable (data on file, Movetis NV). Interestingly, the
persistent nature of the interaction of the two benzofurancar-
boxamides, prucalopride and M0003, shows many similarities
to xanomeline, a muscarinic M1 acetylcholine receptor
(mAChR) agonist (Christopoulos et al., 1998; De Lorme et al.,
2007): (i) resistance to extensive washout and persistent ago-
nistic effect; (ii) concentration dependency of this effect; and
(iii) susceptibility to reversal by the addition of the antagonist
atropine. For xanomeline, a model was proposed that incor-
porated two possible modes of interaction for this ligand with
the M1 receptor (Christopoulos et al., 1998). The first mode
involves a reversible, syntopic interaction with the classic
binding site on the receptor, shared by other agonists or
antagonists. The second mode involves the subsequent devel-
opment of a persistent attachment with specific receptor
regions that allowed xanomeline to continue to activate the
M1 mAChR via the classic binding site but did not allow it to
be readily removed from the receptor compartment. In con-
trast to 5-HT, prucalopride and M0003 have the structural
features to interact in a hydrophobic binding pocket on the
5-HT4 receptor (Rivail et al., 2004; De Maeyer et al., 2008).
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Figure 6 The effect of 0.1 mmol·L-1 prucalopride on the EFS-
induced contractions of longitudinal muscle strips of the proximal
stomach. GR113808 (0.1 mmol·L-1) was added in the presence of
prucalopride. Data points represent six individual experiments and
are connected by a line, for each tissue. Experiments were performed
in the presence of L-NAME (0.1 mmol·L-1) and indomethacin
(1 mmol·L-1) and methysergide (1 mmol·L-1). Similar results were
obtained with M0003.
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This pocket might fulfil the role of the wash-resistant binding
site. However, whether prucalopride and M0003 do, indeed,
interact with the 5-HT4 receptor in a way similar to that of
xanomeline with M1 receptors, needs further investigation.
Atrium
In order to evaluate the long-term off-target effects of 5-HT,
prucalopride and M0003, these compounds were also studied
in the porcine left atrium. Next to human, the pig is one of
the few animals expressing functional 5-HT4 receptors in the
heart. In contrast to the response in gastric tissue, the increase
in contraction force upon application of 5-HT rapidly faded
and was not reproducible after washout. Because we only
monitored changes in the EFS-induced contraction-relaxation
cycle, we cannot deduce the exact underlying mechanism of
this response desensitization. Several mechanisms might be
involved, each contributing to the observed diminishing
response and these mechanisms will be discussed below.
We previously described that the transient nature of the
influence of 5-HT on electrically induced atrial contractions
does not result from ligand breakdown but involves the
recruitment of PDEs, limiting the magnitude and duration of
cAMP signals elicited by a 5-HT4 receptor agonist in the atrial
tissue (De Maeyer et al., 2006a). In a recent abstract, using
paced left atrium of newborn piglets, Vargas et al. (2006)
showed that after a 2 min incubation period with 10 mmol·L-1
5-HT, left atrial contraction force was increased but not the
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Figure 7 Desensitization of the 5-HT4 receptor-mediated responses induced by 5-HT in left atrial pectinate muscles (c, d, e, f). The protocol
(protocol C) of the desensitization experiment is illustrated at the top of the figure. Panels on the right (b, d, f) represent experiments in the
presence of IBMX. Atrial tissues were incubated with different concentrations of 5-HT for 30 min (desensitization period from D to W). The time
course of the 5-HT-induced effects in the atrium is shown in (a). After 30 min, tissues were washed (W) to remove 5-HT and a concentration-
response curve to 5-HT was established. Responses were expressed relative to the baseline at time point x (c, d) or at time point y (e, f). Atrial
experiments were terminated by the administration of a supramaximal concentration of isoprenaline (0.1 mmol·L-1) and responses were
expressed relative to the effect caused by this b-adrenoreceptor agonist.
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(global) left atrial cAMP levels. After 20 min, the inotropic
response had faded while cAMP levels were markedly
increased. In the presence of PDE3 and PDE4 inhibitors, the
inotropic response as well as the tissue cAMP levels were
increased after 2 min and still increased after 20 min. This
confirms the involvement of PDEs in the fading response and
suggests that PDEs contribute to the compartmentation of the
5-HT4 receptor-mediated cAMP signalling pathway in the left
atrium by limiting the diffusion of the second messenger. PDE
activation might provide a framework for a negative feedback
that controls global cAMP homeostasis beneath the mem-
brane. The inhibition of PDEs therefore generates a condition
that is very different from the physiological situation, with no
control over subsarcolemal cAMP levels (Fischmeister et al.,
2006).
Still, it is conceivable that the 5-HT4 receptor-mediated ino-
tropic response is affected not only by PDE recruitment, but
also by receptor desensitization (inactivation), by analogy
with b2-adrenoreceptors for which the transient cAMP
response in HEK-293 cells could be explained by a GRK-b-
arrestin-mediated receptor inactivation as well as a PKA-
mediated induction of PDE activity (Rochais et al., 2004;
Violin et al., 2008). In recombinant systems, 5-HT4 receptor
activation has indeed been shown to be followed by rapid
receptor desensitization through a process involving GRK and
b-arrestin (Barthet et al., 2005; Ponimaskin et al., 2005). The
results obtained in protocol C showed that the pEC50 and
the maximal response of the concentration-response curve
for the inotropic effect of 5-HT were decreased after pre-
treatment with 5-HT, also in the presence of the PDE inhibitor
IBMX. This also implies that the decreased inotropic response
upon repeated administration of 5-HT is not a purely PDE-
mediated phenomenon, although inhibition of PDE activity
by IBMX might not be complete.
The expression level of 5-HT4 receptors in the atrium is very
low, i.e. ~0.3 and ~4 fmol·mg-1 protein in newborn piglets and
adult man, respectively (Kaumann et al., 1995; 1996), com-
pared with ~ 225 fmol·mg-1 protein in human brain (Dome-
nech et al., 1994). Additionally, in contrast to gastric tissue,
there is no 5-HT4 receptor reserve for 5-HT in atrial tissue (De
Maeyer et al., 2006b). This might explain why, in atria in
contrast to gastric tissue, there is a robust desensitization of
the response to 5-HT.
We do acknowledge two additional factors that might have
added to the observed diminishing response to 5-HT. One
factor is the incomplete washout of prucalopride and M0003.
As described above, our data obtained with gastric tissue
indeed suggest an antagonist-reversible but wash-resistant
receptor interaction of these agonists. Both agonists, as well as
GR113808, have the structural features to interact in a hydro-
phobic binding pocket on the 5-HT4 receptor, putatively ful-
filling the role of a wash-resistant binding site. In the atrium,
the response to these agonists already fades during the expo-
sure period because of PDE recruitment and this could hide
the fact that they are still present after the washing step. If the
agonists are bound in a wash-resistant way, they could act as
an antagonist for subsequently administered 5-HT; antago-
nism of 5-HT was previously shown for prucalopride at
human and porcine atrial 5-HT4 receptors (Krobert et al.,
2005). Beyond these considerations, because the agonists are
still bound to the receptor after the washing step, PDE recruit-
ment would persist at the time of 5-HT administration. In the
experiments with 5-HT itself as desensitizing agent in the
presence of IBMX, the 5-HT-induced response was maintained
during the desensitizing exposure period and after washout,
theoretically suggesting that wash-resistant binding might
also occur for 5-HT. We are, however, not aware of any reports
on wash-resistant binding of 5-HT to the 5-HT4 receptor.
The second contributing factor can be found in the activa-
tion of the lusitropic apparatus. We previously demonstrated
that 5-HT4 receptor activation caused a non-transient lusi-
tropic effect which is resistant to inhibition by PDEs (De
Maeyer et al., 2006a). We now show that this enhancement of
cardiac diastolic muscle relaxation is also resistant to drug
washout. The effect of 5-HT4 stimulation in accelerating relax-
ation is believed to involve a combination of an increased rate
of SR Ca2+ uptake due to phospholamban (PLB) phosphoryla-
tion, and a reduction in myofilament Ca2+ sensitivity and an
increase in cross-bridge cycling rate due to troponin I (TnI)
phosphorylation (Li et al., 2000; Birkeland et al., 2007). Our
Table 1 Curve parameters for concentration-effect curves of the left atrial inotropic effect of 5-HT upon pre-treatment with different
concentrations of 5-HT
Desensitizing 5-HT
concentration
No IBMX IBMX
pEC50 Maximal effect pEC50 Maximal effect
Solvent 6.98  0.05 38.8  5.0 7.72  0.13 90.2  4.7
1 nmol·L-1 nd nd 7.64  0.14 94.4  7.1
3 nmol·L-1 6.95  0.14 34.7  6.1 7.75  0.14 87.2  5.9
10 nmol·L-1 6.98  0.07 44.8  4.0 7.69  0.12 83.7  1.8
30 nmol·L-1 6.92  0.05 41.6  4.3 7.67  0.09 89.5  8.2
0.1 mmol·L-1 6.84  0.08 41.15  5.5 7.59  0.14 86.2  3.8
0.3 mmol·L-1 6.83  0.04 25.5  3.1 7.48  0.04 86.5  5.6
1 mmol·L-1 6.64  0.06* 23.2  2.8* 7.23  0.09* 64.3  3.8*
3 mmol·L-1 6.47  0.08** 13.6  1.4** 6.74  0.09** 56.1  9.8**
10 mmol·L-1 6.54  0.15** 9.90  2.1** 6.55  0.18** 33.7  9**
The data used for fitting were those expressed relative to the baseline at time point y (see Figure 7). Data were obtained using tissues from six animals and are
presented as mean  SEM (n = 6). *P < 0.05, **P < 0.01 versus solvent-treated tissues.
nd: not determined.
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results suggest that neither PDEs nor drug washout interferes
with the different intracellular processes involved in the posi-
tive lusitropic effect of 5-HT4 receptor stimulation. This can be
explained by the slow dephosphorylation rates for PLB and
TnI (Garvey et al., 1988). The relative contribution of both
proteins to the lusitropic effect is highly dependent on the
loading conditions (Li et al., 2000). It has been suggested that
under isometric conditions, because of an increased sensitiv-
ity of myofilament for Ca2+ in such heavy loading conditions,
the relaxation time course is mainly determined by Ca2+ dis-
sociating from troponin C, and that the lusitropic coefficient
R2 indirectly reflects myofilament Ca2+ sensitivity (Hanouz
et al., 1998). A primary role for TnI is indirectly supported by
our results because the lusitropic response was still main-
tained after fade of the inotropic response. Because phospho-
rylation of PLB also has an inotropic effect by increasing Ca2+
load of the SR (Birkeland et al., 2007), one would not expect
fading to basal values. The situation might be different when
blocking PDEs, because this disrupts spatially compartmental-
ized cAMP production (Rochais et al., 2004). The involvement
of long-term phosphorylation of PLB in the wash-resistant
positive inotropic effect of high concentrations of 5-HT in the
presence of IBMX can be ruled out by the ability of GR113808
to reverse this maintained response to 5-HT (preliminary
results not shown). The long-term activation of the lusitropic
machinery implies that the effect of 5-HT4 receptor activation
on the subsequent response to 5-HT was assessed under con-
ditions of reduced Ca2+ sensitivity of the myofilaments, which
might in part explain the desensitized inotropic responses to
5-HT.
Because the inotropic effects of prucalopride and M0003
were very small, these compounds allowed us to examine
further the desensitization properties of left atrial 5-HT4
receptor-mediated responses. For many GPCRs there is a
good correlation between agonist efficacy and the ability to
induce receptor desensitization (Clark et al., 1999). However,
pre-treatment with prucalopride or M0003 very effectively
blunted the response to 5-HT, arguing against this generali-
zation. This finding can be interpreted in three ways. First,
in colliculi neurons, a good correlation was found between
the potencies of several 5-HT4 receptor agonists and their
abilities to desensitize the adenylyl cyclase response
(Ansanay et al., 1992). According to the authors, the depen-
dence on potency, and not on efficacy, reflects the influence
of the agonists’ binding affinity or its mean occupancy time
of the receptor. Our results fit into this theory because pre-
treatment with prucalopride or M0003 very effectively
blunted the response to 5-HT with a potency proportional
to their 5-HT4 receptor affinity. Second, the correlation with
affinity is also in accordance with antagonism by residually
bound agonist (see above). Finally, this can also be inter-
preted in light of ‘functional selectivity’. The idea that dif-
ferent agonists are able to produce different response profiles
by stabilizing different receptor conformations and activat-
ing different signal transduction pathways or mechanisms of
desensitization is extending (Kelly et al., 2008). This has
clearly been shown for the m-opioid receptor for which it
has been demonstrated that different agonists induce differ-
ent mechanisms of m-opioid receptor desensitization (Kelly
et al., 2008).
In conclusion, our results show a clear-cut difference
between the desensitization of the 5-HT4 receptor-mediated
responses in stomach and left atrium. In the stomach, the
responses were only apparently desensitized while in the
atrium the responses to 5-HT were clearly not reproducible. In
addition to the efficacy differences of 5-HT4 receptor agonists
such as prucalopride and M0003 in stomach versus atrium
(De Maeyer et al., 2006b), the phenomenon might contribute
to tissue selectivity of 5-HT4 receptor agonists.
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Figure 8 Concentration-dependent decrease of R2, shown as
D(+dF·dt-1)/(-dF·dt-1), measured after washout of 5-HT, prucalopride
or M0003 following a 1 h incubation with these compounds. On
average, the basal value of R2 was 1.41  0.04 (n = 30), 1.46  0.04
(n = 36) and 1.44  0.03 (n = 36) in the experiments with 5-HT,
prucalopride and M0003 respectively. Data were analysed using one-
way ANOVA with Dunnett’s post hoc test (*P < 0.05, **P < 0.01 versus
solvent-treated tissues). For all compounds, a significant trend
between the effect and desensitizing concentration was found
(P < 0.001).
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